AlloVir, Inc. (NASDAQ:ALVR - Get Free Report) shares were up 8.2% during mid-day trading on Friday . The stock traded as high as $9.50 and last traded at $9.74. 34,835 shares changed hands during trading, a decline of 2% from the average daily volume of 35,517 shares. The stock had previously closed at $9.00.
AlloVir Trading Up 4.9 %
The company has a market capitalization of $1.09 billion, a PE ratio of -10.73 and a beta of 0.65. The business has a fifty day moving average of $0.67 and a 200 day moving average of $0.74.
AlloVir (NASDAQ:ALVR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10.
Institutional Trading of AlloVir
A hedge fund recently raised its stake in AlloVir stock. Cubist Systematic Strategies LLC boosted its stake in shares of AlloVir, Inc. (NASDAQ:ALVR - Free Report) by 152.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,816 shares of the company's stock after purchasing an additional 30,072 shares during the quarter. Cubist Systematic Strategies LLC's holdings in AlloVir were worth $36,000 as of its most recent SEC filing. Institutional investors own 66.05% of the company's stock.
About AlloVir
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AlloVir, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AlloVir wasn't on the list.
While AlloVir currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
